• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Uganda declares Ebola Virus Disease outbreak (SEBOV) - 20 Sept 2022 - Outbreak is over

Ebola cases rise in the Ugandan capital, Kampala

​​​​​​By Africanews

Last updated: 6 hours ago

Health authorities in Uganda announced that at least 15 people had contracted the deadly Ebola virus in the capital, Kampala.

Kampala becomes the sixth district to confirm the presence of the virus after the outbreak was first identified in the district of Mubende....:tiphat:
https://www.africanews.com/2022/10/24/ebola-cases-rise-in-the-ugandan-capital-kampala/
 
Mukono VHTs in Ebola sensitisation drive as Kampala reports 15 cases

Monday, October 24, 2022

By Jessica Sabano
Village health teams in Mukono District have intensified their senstisation drive about Ebola outbreak after the neighbouring capital, Kampala reported 15 confirmed cases.
Ms Ritah Nakigozi a village health team member in Goma division Mukono municipality said they had started outreaches to communities to make them aware of Eb...
:tiphat:https://www.monitor.co.ug/uganda/ne...ive-as-kampala-reports-15-cases-3996664​​​​​​
 
Thailand

Suvarnabhumi screening arrivals from DR Congo for Ebola



MONDAY, OCTOBER 24, 2022

Suvarnabhumi Airport has begun screening arrivals from DR Congo for symptoms of Ebola after the deadly virus began spreading from neighbouring Uganda.


All foreign arrivals who have been to DR Congo in the past 21 days must undergo thermal scanning and provide their travel history and their address and telephone number in Thailand. They will receive a health beware card for self-monitoring that contains contact numbers in case of emergency.

Suvarnabhumi is screening DR Congo arrivals for symptoms of body temperature over 38 degrees Celsius, fever, headache, muscle ache, sore throat, fatigue or a history of potential exposure to infected cases. Travellers who display these symptoms will be tested, monitored, or sent to Bamrasnaradura Infectious Diseases Institute in Bangkok, according to the Disease Control Department....:tiphat:https://www.nationmultimedia.com/tha...neral/40021350
 
15 cases of Ebola in Kampala, seven from one family in Masanafu
9hoursago.
The Ministry of Health is treating seven members of one family who tested positive for Ebola in Kampala after they came into contact with a relative who travelled from Kassanda district before it was locked down just over a week ago. The Director General of Health Services, Dr. Henry Mwebesa, says the seven had already been isolated by the time their tests returned positive for Ebola.
video https://www.ntv.co.ug/ug/news/15-cases-of-ebola-in-kampala-seven-from-one-family-in-masanafu-3996604
 
Ministry of Health- Uganda
@MinofHealthUG
·9h
#EbolaOutbreakUG update as of 24 October 2022

Ff5T0EQXkAEAuFB
 
U.S. Embassy in Uganda


Health Alert – Update on Ebola Situation



Home | News & Events | Health Alert – Update on Ebola Situation
Health-Alert.jpeg


Health Alert – Update on Ebola Situation

Location: Uganda

Event: As of October 25, 2022, the Uganda Ministry of Health (MoH) has reported 95 confirmed Sudan Ebolavirus (SUDV) cases, 28 confirmed deaths and 34 recoveries. On October 16, 2022, President Yoweri Museveni declared a three-week lockdown in Mubende and Kassanda districts in an effort to contain the spread of the current outbreak of SUDV. The Ministry of Health and partners in Uganda are implementing multiple interventions in affected and surrounding districts in order to contain and control the spread of the disease. The U.S. Centers for Disease Control and Prevention (CDC) announced that as of October 11, 2022, the United States would re-direct all U.S.-bound travelers who traveled from or were present in Uganda in the previous 21 days to five U.S. airports for health screening.

Actions to take:
  • Monitor U.S. Embassy Kampala, Uganda’s public messaging regarding the outbreak of SUDV in Uganda here: https://ug.usembassy.gov/u-s-citizen...l-information/
  • Review the U.S. CDC’s Level 2 Travel Health Notice for Uganda: https://wwwnc.cdc.gov/travel/notices...bola-in-uganda
  • Find more information about Ebola Virus Disease (EVD) on https://www.cdc.gov/vhf/ebola/
  • Monitor the Government of Uganda’s Ministry of Health website and twitter account for latest Ebola updates and guidance on movement restrictions
  • Avoid contact with dead bodies, blood, and other body fluids from people who are symptomatic or from contaminated surfaces. A person can only spread Ebola to other people after they develop signs and symptoms of Ebola (e.g., fever, sore throat, diarrhea, vomiting, headache, and abdominal pain)
  • Avoid contact with bats, forest antelopes, and non-human primates and raw meat prepared from these or unknown animals (bushmeat)
  • Defer non-essential travel to Mubende and Kassanda districts. If you reside in or must travel through these districts, obey the instructions of Ugandan authorities with regard to measures to control the outbreak.
  • Be particularly vigilant about potential exposure when accessing health care facilities in Uganda
Assistance: 
By U.S. Mission Uganda | 25 October, 2022 | Topics: Alert, U.S. Citizen Services


https://ug.usembassy.gov/health-alert-update-on-ebola-situation/
 
Uganda Medical Association leader calls for Kampala lockdown

By AT editor - 25 October 2022 at 9:38 pm

The head of the Uganda Medical Association says officials need to consider a lockdown in Kampala as the Ebola case count continues to rise in the capital.

Dr. Samuel Oledo told local media outlets that he fears the worst is yet to come if aggressive measures aren’t taken quickly. The number of Ebola cases in Kampala has risen to 15, adding new infections in just the past 48 hours....

“Kampala should have restriction of movement, let us hold Kampala when it is still early. The earlier we lockdown Kampala the better,” Oledo told KFM radio. “Ugandans are still taking it as something so minor. It is catastrophic that right now, people are not even reporting cases,”...

..​​​​​​
While the Ministry of Health has been successful in identifying cases and monitoring contacts, the response is complicated by people with Ebola exposure who are hiding from authorities and fleeing health centers, as well as those seeking out traditional healers...
:tiphat:https://africatimes.com/2022/10/25/...er-calls-for-ebola-lockdown-in-kampala/​​​​​​
 
Kakumiro authorities close market over invasion of traders from Mubende

Tuesday, October 25, 2022
  • The market located in Kakumiro town was flooded with hundreds of traders from Mubende, Kasanda, Mityana, Kibaale, Kyankwanzi, Hoima and Kagadi among other districts.
The authorities in Kakumiro District on Tuesday morning closed the Kakumiro town council weekly market after traders from Ebola-hit areas flooded the market.
...“People who have come here claim to have come from Kampala, Mityana but there are some who have come from Ebola hit-districts of Mubende and Kasanda. We have now ordered them to leave the market,” he said.

The Kakumiro District chairman, Mr Joseph Sentayi said: “I got several calls from our local vendors informing us of some traders who have come from Mubende and Kasanda districts. We are doing it for the sake of preventing the spread of Ebola.”...

Ms Janipher Kinyenye, a local food vendor wondered how traders from Mubende and Kasanda beat security checkpoints to cross over to Kakumiro District.....
:tiphat:https://www.monitor.co.ug/uganda/ne...nvasion-of-traders-from-mubende-3997566​​​​​​
 
Many U.S. labs cannot test for Ebola strain behind Uganda's swelling outbreak


BY ALEXANDER TIN

OCTOBER 25, 2022 / 7:48 PM / CBS NEWS

The Biden administration is racing to expand the number of U.S. labs that are able to test for the virus behind a swelling Ebola outbreak in Uganda, as health officials prepare for what they say remains an unlikely but real possibility that the virus could enter the country.

Most of the tests that were rolled out around the U.S. during a previous Ebola scare in 2014, which involved a strain known as Zaire Ebolavirus, were never authorized by the Food and Drug Administration to be used for diagnosing the Sudan strain, which is behind the current surge in Uganda......A few weeks ago, only eight members of the publicly-funded Laboratory Response Network had the ability to test for the virus, Choi said.

That number has now risen to 22 labs across the network, a CDC spokesperson said Tuesday....

:tiphat:https://www.cbsnews.com/news/ebola-virus-outbreak-us-labs-test-uganda/​​​​​​
 
Merck Responds to Sudan Ebolavirus Outbreak in Uganda with Plans to Produce and Donate Investigational Vaccine Doses for IAVI’s Vaccine Development Program

October 25, 2022 7:00 am ET

RAHWAY, N.J., Oct. 25, 2022 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that in response to the health and humanitarian crisis of the Sudan ebolavirus outbreak in Uganda, the company plans to produce and donate vials of investigational candidate Sudan ebolavirus vaccine to IAVI, a global nonprofit scientific research organization, for further clinical research use. IAVI plans to use these vials for its ongoing Sudan ebolavirus vaccine development program. The vials will be produced from existing investigational bulk drug substance previously manufactured by Merck and are intended to be used as part of the World Health Organization’s (WHO’s) efforts to fight the outbreak in Uganda. Merck and IAVI are working toward a formal agreement and are collaborating now to accelerate this effort.

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Merck anticipates that it will fill approximately 50,000 doses for IAVI from the existing bulk drug substance by the end of 2022. Further use in the response to the outbreak will be subject to authorization by applicable health authorities.

Dr. Mark Feinberg, president and CEO of IAVI, said, “We are very grateful to Merck for supplying the investigational vaccine for IAVI, which will help accelerate IAVI’s program. IAVI looks forward to working with partners responding to the ongoing Sudan Ebola outbreak to evaluate vaccine effectiveness and safety. We hope that our efforts may contribute to the response in Uganda should the outbreak persist, and also enable the world to be better prepared for future Sudan Ebola outbreaks.”

The vials of investigational Sudan ebolavirus vaccine to be donated by Merck use a replication-competent, live, attenuated recombinant vesicular stomatitis virus (rVSV) vaccine construct similar to that used for ERVEBO[SUP]® [/SUP](Ebola Zaire Vaccine, Live), the company’s vaccine approved for the prevention of disease caused by Zaire ebolavirus in individuals 18 years and older as a single dose administration. Over the past 20 years, Zaire ebolavirus has been the most common cause of Ebola outbreaks. ERVEBO does not protect against other species of Ebolavirus, including the Sudan ebolavirus.

About ERVEBO[SUP]® ([/SUP]Ebola Zaire Vaccine, Live)

ERVEBO was initially engineered by scientists from the Public Health Agency of Canada’s National Microbiology Laboratory and the technology was subsequently licensed by a subsidiary of NewLink Genetics Corporation now known as Lumos Pharma, Inc. ERVEBO is approved in the European Union, United Kingdom, United States, Switzerland, and 10 countries in Africa.

In the United States, ERVEBO is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. The duration of protection conferred by ERVEBO is unknown. ERVEBO does not protect against other species of Ebolavirus or Marburgvirus. Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

Selected Safety Information for ERVEBO

WARNINGS AND PRECAUTIONS

Management of Acute Allergic Reactions

Among 15,399 subjects vaccinated with ERVEBO, there were two reports of anaphylaxis. Monitor individuals for signs and symptoms of hypersensitivity reactions following vaccination with ERVEBO. Appropriate medical treatment and supervision must be available in case of an anaphylactic event following the administration of ERVEBO.

Limitations of Vaccine Effectiveness

Vaccination with ERVEBO may not protect all individuals. Vaccinated individuals should continue to adhere to infection control practices to prevent Zaire ebolavirus infection and transmission.

Immunocompromised Individuals

The safety and effectiveness of ERVEBO have not been assessed in immunocompromised individuals. The effectiveness of ERVEBO in immunocompromised individuals may be diminished. The risk of vaccination with ERVEBO, a live virus vaccine, in immunocompromised individuals should be weighed against the risk of disease due to Zaire ebolavirus.

Transmission

Vaccine virus RNA has been detected by RT-PCR in blood, saliva, urine, and fluid from skin vesicles of vaccinated adults. Transmission of vaccine virus is a theoretical possibility.

ADVERSE REACTIONS

The most common injection-site adverse reactions reported by subjects taking ERVEBO in Study 1 (N=500) were injection-site pain (34.0%) and redness/swelling (2%). The most common systemic adverse reactions reported following vaccination with ERVEBO in Study 1 (N=498) were headache (37%), feverishness (34%), muscle pain (33%), fatigue (19%), nausea (8%), joint pain/tenderness (7%), rash (4%), and abnormal sweating (3%). Study 1 was conducted in Liberia (N=1,000). Subjects were randomized 1:1 to receive ERVEBO or saline placebo and were assessed at Week 1 and Month 1 postvaccination for solicited local and systemic reactions. In a subset of subjects (n=201), joint symptoms and signs were also solicited during a Week 2 visit.

The most common injection-site adverse reactions reported by subjects taking ERVEBO in Study 2 (N=1051) were injection-site pain (70.0%), swelling (17%), and redness (12%). The most common systemic adverse reactions reported following vaccination with ERVEBO in Study 2 (N=1051) were joint pain (18%), arthritis (5%), rash (4%), and vesicular lesions (2%). Study 2 was conducted in the United States, Canada, and Spain (N=1,197). Subjects were randomized to receive ERVEBO (n=1,061) or saline placebo (n=133). Subjects recorded solicited local reactions from Days 1 to 5 postvaccination, and daily temperature measurements and solicited joint and skin events from Days 1 to 42 postvaccination.

DRUG INTERACTIONS

Interference with Laboratory Tests

Following vaccination with ERVEBO, individuals may test positive for anti-Ebola glycoprotein (GP) antibody and/or Ebola GP nucleic acid or antigens. GP-based testing may have limited diagnostic value during the period of vaccine viremia, in the presence of vaccine-derived Ebola GP, and following antibody response to the vaccine.

USE IN SPECIFIC POPULATIONS

There are no adequate and well-controlled studies of ERVEBO in pregnant women, and human data available from clinical trials with ERVEBO are insufficient to establish the presence or absence of vaccine-associated risk during pregnancy.

Human data are not available to assess the impact of ERVEBO on milk production, its presence in breast milk, or its effects on the breastfed child.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

https://www.merck.com/news/merck-re...-doses-for-iavis-vaccine-development-program/
 
KCCA Conducts Transport Surveillance to Shield Kampala from Ebola

Kampala, Uganda
Dr. Alex Ndyabakira, the City Incident Commander at KCCA, says that to shield Kampala from Ebola victims entering and interacting with communities, they have put in place field surveillance officers who keep track of the automobiles like taxis and buses that enter or exit the city.
25 Oct 2022 19:24
 
Thailand now monitoring all arrivals from Africa to prevent spread of Ebola
  • October 25, 2022
​​​​​​The Thai Ministry of Public Health has stepped up its monitoring of arrivals from African countries, especially Uganda, following an outbreak of Ebola in that country in September, said Dr. Tares Krassanairawiwong, director-general of Disease Control Department today (Tuesday).

He said that, even though the World Health Organisation (WHO) has not yet issued a Public Health Emergency of International Concern (PHEIC) notice, he finds it necessary for Thailand to take the precaution, to prevent the disease from entering the country.

Citing Ebola as a dangerous infectious disease, Dr. Tares said that all arrivals from Uganda are required to undergo health screening and to register their arrival at their port of entry, before they will be allowed into the country....
:tiphat:https://www.thaipbsworld.com/thaila...ivals-from-africa-to-prevent-spread-of-ebola/
 
Kawaala health centre III registers 5 suspected Ebola cases
  • October 25,
  • Kawaala health centre III in Lubaga Division has registered five suspected Ebola cases. The suspects comprise three women, one man, and a child below three years of age, who came to the facility with one of the female suspects.

    A health worker at the facility, says the male suspect called them whimpering, and expressed fears that he could have contracted the Ebola virus. The man, who was bleeding from different openings of his body and had a fever, told the health workers that he had contact with some people from Mubende district recently....Health workers were heard complaining that they had called for an ambulance from the ministry of Health to pick up the suspects since morning but to no avail. URN spent over an hour at the facility and by the time our report left, the suspects were yet to be evacuated.
  • .....
:tiphat:https://observer.ug/news/headlines/...e-iii-registers-5-suspected-ebola-cases​​​​​​
 
Source: https://abcnews.go.com/Health/wireS...hoolkids-uganda-contagion-fear-grows-92123240

Ebola infects 6 schoolkids in Uganda as contagion fear grows

Six schoolchildren in Uganda’s capital have tested positive for Ebola
ByRODNEY MUHUMUZA Associated Press
October 26, 2022, 11:47 AM

KAMPALA, Uganda -- Six schoolchildren in Uganda’s capital have tested positive for Ebola, the health minister said Wednesday, marking a serious escalation of the outbreak declared just over a month ago.

The children, who attend three different schools in Kampala, are among at least 15 people in the city confirmed to have been infected with Ebola, according to a statement by Health Minister Jane Ruth Aceng.

The children are members of a family exposed to the disease by a man who traveled from one Ebola-hit district, sought treatment in Kampala and died there, the statement said.

“He is responsible for infecting the family of seven, including the neighbors and many others,” the statement said, speaking of the traveling Ebola patient. “We were able to get this cluster, plus one other, because of the ministry’s vigilance in contact tracing and field case management.”

Authorities are “following up” 170 contacts from schools the six children attend, it said...
 
WEEKLY BULLETIN ON OUTBREAKS
AND OTHER EMERGENCIES

Week 43: 17 - 23 October 2022
Data as reported by: 17:00; 23 October 2022

...

Ebola Virus Disease caused by Sudan virus in Uganda

90 cases
28 Deaths
31.0% CFR


EVENT DESCRIPTION

The Ebola disease caused by Sudan ebolavirus (named Sudan
virus disease, SVD) outbreak has been ongoing in Uganda since 19
September 2022, following confirmation in a 24-year old patient
in Madudu Sub-County of Mubende District. As of 23 October
2022, a total 90 laboratory-confirmed and 20 probable cases
have been reported. Forty-eight fatalities have been registered
including 28 confirmed cases, for an overall case fatality ratio of
46.0%, and 31.0% among confirmed cases. A total of 32 patients
have been discharged, giving a recovery rate of 36.0%. A total of
13 healthcare workers have been affected, of whom four (31.0%)
have died.

Two new Districts have reported cases of SVD, including
Kampala and Wakiso. Cumulatively, seven Districts have so
far been affected: Mubende, which remains the epicentre (60
confirmed and 19 probable), Kassanda (10 confirmed and one
probable), Kampala (14 confirmed), Kyegegwa (three confirmed),
Bunyangabu (one confirmed), Kagadi (one confirmed), and
Wakiso (one confirmed). Of note, no new cases of SVD have been
reported in Bunyangabu, Kagadi and Kyegegwa districts since the
symptom onset of the last confirmed cases, respectively for 24,
26 and 32 days.

A total of 2 430 contacts have been listed around confirmed and
probable cases of SVD since the beginning of the outbreak, in
13 districts including Bunyangabu, Luweero, Fort Portal City,
Kagadi, Kakumiro, Kampala, Kassanda, Kyegegwa, Mitooma,
Mityana, Mubende, Nakasongola, and Ntungamo. All listed
contacts in Bunyangabu, Fort Portal City, Kagadi, and Kyegegwa
have completed 21 days of follow-up. Currently, 1 237 contacts
are actively followed-up in nine Districts, of which 1 161 (94%)
have been seen over the past 24hrs. In addition, several alerts are
being received and validated across the country.

PUBLIC HEALTH ACTIONS

Coordination

Epidemiological investigations, contact tracing, and active
case finding are ongoing in all affected Districts. As of 23
October 2022, 1 237 contacts were still under follow-up,
with 1 161 (94.0%) followed-up over the past 24hrs. A
total of 118 alerts were received nationwide, all of whom
were verified; 58 (49.0%) of them were validated as new
suspected cases and 37 (64.0%) were evacuated to Ebola
Treatment Units (ETUs).

Eighty surveillance officers in Makindye and Rubaga divisions
of Kampala Capital City Authority (KCCA) were trained on
active case finding, case investigation and contact tracing.
Go-Data accounts were created, and data were harmonized.
Orientation of ten contact tracers at community level was
done in Mityana District

A mobile laboratory remains operational at the Mubende ETU
with adequate test kits facilitating timely sample collection,
testing and release of results within six hours.

Cumulatively, 1 009 samples have been collected and tested
since the beginning of the outbreak, yielding 90 confirmed
cases.

Ninety laboratory personnel in KCCA were trained on sample
collection, transportation, biosafety and biosecurity across
the divisions.

Case management and psychosocial support

Three ETUs, one each in Mubende, Entebbe and Madudu are
fully operational. Cumulatively, 32 (36.0%) recoveries have
so far been recorded.

A symposium has been organised on SVD management,
attended by healthcare workers across the country as well as
international consultants, and during which field experiences
were shared.

A tent has been set-up in Bunyangabu District to act as a
holding place for suspected cases of SVD.

The Emergency Medical Services call centres are now fully
operational in Kassanda, KCCA and Mubende. A total of 45
evacuations have been done in Kassanda, 29 in Mubende,
three in Kampala, one in Kagadi, one in Kakumiro, and one
in Ntungamo.

Psychosocial support continues to be offered to suspected
and confirmed cases in ETUs, as well as to their family
members. Pre-test (and post-test) counselling are also being
offered to all patients at ETUs, and to contacts. In addition, the
resettling of the discharged persons and negative suspected
cases into their community continues.

Infection, prevention and control (IPC)

Daily monitoring of IPC measures in ETUs is still ongoing.

A mentorship session was organised in KCCA, conveying 30
IPC mentors on proper personal protective equipment (PPE)
donning and doffing, risk assessment, preparing chlorine
solutions, setting-up screening and isolation area and no
touch care for suspected cases.

In Mubende, an IPC Compliance Team was formulated
at ETU, comprising all pillar leads; an IPC orientation was
resolved to be conducted for this team, and the ETU work
plan was developed.

In Kassanda, 18 IPC focal persons from 18 healthcare facilities
have been oriented. An action plan was drawn which shall be
implemented in the respective 18 healthcare facilities.

An orientation was conducted for 21 Mubende ETU hygienists
on the cleaning and decontamination procedure, PPE use
and preparation of chlorine solution.

A total of 51 IPC mentors from Nakawa and Rubaga Divisions
have been trained on basic IPC and use of the IPC score card.
They are expected to cascade the training to IPC focal persons
in the different healthcare facilities of these Divisions.

Four safe and dignified burials have been conducted in
Mubende were conducted in the past 24hours. In addition,
the burial team in Kassanda has been trained.

Risk communication and community engagement

RCCE interventions are ongoing in all affected Districts and
beyond.

There are ongoing media activities in Mubende and Kassanda
including radio talk shows. A total of 15 radio spots continue
to run daily, and community audio tower messages continue
to run in 10 hotspot areas.

RCCE Team in Kassanda worked with the contact tracing
pillar members to address stigmatization in Kalamba village
following confirmation of SVD cases in that village. Together
with the Local Council (LCI) chairman, the team sensitized
the residents on the signs, symptoms, and prevention
of SVD, care for patients, and on the importance of early
reporting.

RCCE Team in Mubende conducted a planning meeting with
the Village Task Force of Kisekende cell - South Division,
attended by the LCI chairman, two village health teams, the
Community Development Officer, and the health assistant.

Logistics

The distribution of supplies in healthcare facilities within all
affected districts is ongoing, including PPE, spray pumps,
wooden pallets, tarpaulin, essential medicines, discharge
packages, fuel, vehicles, stationery, digital thermometers,
infra-red thermometers from MoH and partners.

Laptop and desktop computers have been offered to support
the response.

An additional 14 mini-buses have been made available to
support movement and transportation of response teams on
ground.

SITUATION INTERPRETATION

The evolution of the ongoing SVD outbreak in Uganda has
been marked by an expansion of the disease to two newly
affected Districts including Kampala. Kampala is the capital
city of Uganda with an estimated population of 4 million
inhabitants, with a density reaching 21 032 hab./km2. Therefore,
if uncontrolled,
the situation would become highly disastrous.

Response interventions need to be rapidly put in place to control
the disease. Fortunately, all cases identified there have been
contacts of known SVD cases and had already been quarantined
since their identification as contacts. Kampala is very close to
an international airport and is not far from the shores of Lake
Victoria, which forms part of the frontier with Kenya and Tanzania.
Therefore, the risk of international spread of the disease is to be
considered.
Accordingly, preparedness and readiness activities
should be reinforced and/or scaled-up in neighbouring countries
and beyond.
...
https://apps.who.int/iris/bitstream/handle/10665/363780/OEW43-1723102022.pdf
 
Back
Top Bottom